Efficacy of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants With Congenital Heart Disease and Chronic Lung Disease: A Pooled Analysis of Randomised Controlled Trials

• 2023

  Sign in to bookmark this resource.

  Sign in
• Eric Simões; Shabir Madhi; William Muller; Victoria Atanasova; Miroslava Bosheva; Fernando Cabañas
PMID: 36634694DOI: https://dx.doi.org/10.1016/S2352-4642(22)00321-2

---

Access Resources

• Journal ArticleEN

About

This article describes a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) infections in infants. It focuses on both preterm and term babies, as well as those with congenital heart disease and chronic lung disease. The research combines data from several trials to understand how well nirsevimab works. It also looks at how the drug behaves in the body of these infants, which is called pharmacokinetic extrapolation. The goal is to see if nirsevimab can help protect vulnerable babies from serious RSV infections that affect their lungs.



---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Heart Defects, Congenital; Infant; Pharmacokinetics; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Respiratory Syncytial Virus, Human; Palivizumab; Antibodies, Monoclonal, Humanized; Infant, Premature

Institutions: Children's Hospital Colorado; University of the Witwatersrand; Northwestern University; Dr. Georgi Stranski University Hospital; Quironsalud Madrid University Hospital; State University of New York - Upstate Medical University

---

More like this

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease 2023 · State University of New York - Upstate Medical University, AstraZeneca, Dr. Georgi Stranski University Hospital, Quironsalud Madrid University Hospital, Fukuoka Children's Hospital, Hôpital Femme-Mere-Enfant Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants 2020 · AstraZeneca, State University of New York - Upstate Medical University, University of the Witwatersrand, University of Colorado, Le Bonheur Children's Hospital, Città della Salute e della Scienza RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing 2024 · AstraZeneca, State University of New York - Upstate Medical University, Seattle Children's Hospital, Northwestern University

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---